Tirzepatide
Tirzepatide Peptide
A dual GIP/GLP-1 receptor agonist offering superior weight loss and glycemic control compared to GLP-1-only medications. The active ingredient in Mounjaro and Zepbound.
Typical Cost
$1000-1600/month (brand), $200-500/month (compounded)
Status
Research
Peptide Profile
Tirzepatide
Mechanism of Action
Activates both GIP and GLP-1 receptors, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite more effectively than GLP-1 agonists alone.
Common Dosages
subcutaneous
2.5-15mg
Weekly · Ongoing
Benefits
Superior weight loss vs GLP-1 only
Improved HbA1c
Reduced cardiovascular risk
Enhanced satiety
Better lipid profiles
Sustained results
Side Effects
Nausea
Vomiting
Diarrhea
Constipation
Injection site reactions
Gallbladder issues
Potential thyroid tumors
Key Research
SURMOUNT-1 - Tirzepatide for obesity
Average 20.9% weight loss at 72 weeks with 15mg dose
SURPASS-2 - vs Semaglutide
Superior HbA1c reduction and weight loss compared to semaglutide 1mg
Regulatory Status
FDA-approved (Mounjaro for diabetes, Zepbound for weight loss). Also available from compounding pharmacies.
Contraindications
- ⚠Medullary thyroid carcinoma history
- ⚠MEN2 syndrome
- ⚠Pregnancy/breastfeeding
- ⚠Personal/family history of pancreatitis
Enhanced GI side effects make SeraVia Gut+ Balance particularly valuable for tirzepatide users managing nausea and digestive discomfort.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.